Replidyne restructured and reduced headcount across all areas by 19 (80%) to 5. The company also suspended development of its sole remaining compound, REP3123, a preclinical methionyl tRNA synthetase (MetRS) inhibitor for Clostridium difficile-associated...

Replidyne said that as part of a restructuring it has decided to suspended development of REP3123, which was in preclinical testing. The company said it is still in the process of reviewing its strategic alternatives...

RDYN restructured and reduced headcount by 27 (33%) to 54. The company also said it will seek strategic alternatives, including making an acquisition, merging or being acquired.
RDYN will continue its ongoing placebo-controlled Phase III...

Dashing the hopes of buysiders, Biogen Idec (BIIB) said it had not received any definitive offers and would remain independent. The announcement came after market close on Wednesday and BIIB plunged $17.97 (24%) to $57.91...

RDYN restructured and reduced headcount to 54 from 81. The company also said it will seek strategic alternatives, including making an acquisition, merging or being acquired.
RDYN will continue its ongoing placebo-controlled Phase III trial...

Cultures taken from patients treated for infected dog- and cat-bite wounds showed that REP8839 was effective against Gram-positive organisms including streptococci and anaerobic peptostreptococci. The methionyl tRNA synthetase (MetRS) inhibitor was also effective against...